Drawing on experiences from treating EGFR gene mutations, the most common oncogenic drivers in non-small cell lung cancer (24), EGFR-TKI targeted therapy may be applicable to patients with AF carrying EGFR mutations. This evidence concerns the gene EGFR and atrial fibrillation.